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ABSTRACT
Background: To produce a practice guideline that includes a set of detailed consensus principles regarding the
prescription of antipsychotics (APs) amongst people with dementia living in care homes.
Methods: We used a modified Delphi consensus procedure with three rounds, where we actively specified
and optimized statements throughout the process, utilizing input from four focus groups, carried out in UK,
Norway, and the Netherlands. This was done to identify relevant themes and a set of statement that experts
agreed upon using the Research and Development/University of California at Los Angeles (RAND/UCLA)
methodology.
Results: A total of 72 scientific and clinical experts and 14 consumer experts reached consensus upon 150
statements covering five themes: (1) General prescription stipulations, (2) assessments prior to prescription,
(3) care and treatment plan, (4) discontinuation, and (5) long-term treatment.
Conclusions: In this practice guideline, novel informationwas provided about detailed indication and thresholds
of symptoms, risk factors, circumstances at which APs should be stopped or tapered, specific criteria for
justifying long-term treatment, involvement of the multidisciplinary team, and family caregiver in the process
of prescription. The practice guideline is based on formal consensus of clinicians and consumer experts and
provides clinicians relevant practical information that is lacking in current guidelines.
Key words: dementia, psychopharmacology, nursing homes
Introduction
APs are widely prescribed for the treatment of
neuropsychiatric symptoms (NPS) for people with
dementia, especially in long-term care settings.
People with dementia in care homes have a higher
risk of AP drug prescription compared to those
residing in the community (Maquire et al., 2013).
Prescription rates range from 20 to 50% with
Correspondence should be addressed to: Sytse U. Zuidema, Department of
General Practice, University of Groningen, University Medical Centre
Groningen, PO Box 196 (HPC FA21), 9700 ADGroningen, the Netherlands.
Phone:+31 6 54971196; Email: s.u.zuidema@umcg.nl. Received 13Oct 2014;
revision requested 25 Jan 2015; revised version received 9 Apr 2015; accepted
17 Apr 2015. First published online 10 June 2015.
some variation among countries (Feng et al., 2009,
Wetzels et al., 2011, Barnes et al., 2012), and
between nursing homes (Selbaek et al., 2008,
Zuidema et al., 2011), This variation is probably
largely explained by differences in clinical and
care practice (Zuidema et al., 2011; Cornegé-
Blokland et al., 2012). Moreover, APs are often
used for prolonged periods of >6 months (Wetzels
et al., 2011, Barnes et al., 2012, Gustafsson et al.,
2013), sometimes without an appropriate ongoing
indication/regular review (Chen et al., 2010)
highlighting non-adherence to current guidelines
(Morley, 2012).
APs have a modest but significant benefit over
a period of 12 weeks in the treatment of both
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aggression and psychosis, but also widely reported
adverse events, like extrapyramidal symptoms,
sedation, falls, accelerated cognitive decline, and
increased risk of stroke, pneumonia, and a 1.5–
1.7 fold increased risk of mortality (Gareri et al.,
2014). APs can be withdrawn without relapse of
NPS (Declerq, et al., 2013), although a small
proportion of people do have a return of symptoms
with cessation or reduction of APs (Ballard et al.,
2009a; Devanand et al., 2012). Moreover, there is
evidence that psychosocial interventions may help
to reduce AP drug use (Richter et al., 2012).
Although prescription rates tend to decrease
in some countries (Health and Social Care
Information Centre, National Dementia and
Antipsychotic Prescribing Audit, 2012; Schulze
et al., 2013), there is still a long way to go
in reducing use of APs and convince physicians
towards more appropriate use. Many physicians
believe that existing evidence-based guidelines are
not adequate for daily practice (McCleery and Fox,
2012). Therefore, there is a need to fill the gap
between the existing evidence and daily practice and
to develop more practice-based recommendations
for appropriate prescription of APs.
Some key topics in the prescription of APs are
not sufficiently addressed in the consensus papers
and other practice guidelines such as the American
Geriatrics Society and American Association
for Geriatric Psychiatry (AGS/AAGP) consensus
statement (AGS/AAGP, 2003), the Canadian
guideline for seniors’ mental health (Conn et al.,
2006), the National Institute for Health and
Care Excellence (NICE) guideline Dementia for
supporting people with dementia and their carers
in health and social care (NICE clinical guideline
42, 2006), and the Behavioral and Psychological
Symptoms in Dementia (BPSD) guide (British
Alzheimer’s Society, 2011). These topics include:
(1) detailed indication and thresholds to prescribe
APs in agitation, aggression, and psychosis, (2)
risk factors that should be considered before
prescription, (3) circumstances at which APs should
be stopped or tapered, (4) specific criteria for
justifying long-term treatment, (5) involvement of
the multidisciplinary team and family caregiver in
the process of AP prescription.
Previous practice guidelines mentioned above
has largely relied on so-called type IV evidence.
The decision process that has led to this kind of
consensus statements are not clearly prescribed in
previous consensus papers and practice guidelines,
may depend on the experts’ own individual
preferences and lacked the direct involvement of
consumer experts.
The aim of this study was to produce a practice
guideline that includes a set of detailed principles re-
garding the prescription of APs amongst people with
dementia living in care homes. The guideline had to
be agreed upon by scientific, clinical, and consumer
experts using a modified Delphi consensus
procedure and really contribute to the key topics
of gaps in scientific knowledge mentioned above.
Methods
Description of the modified Delphi consensus
procedure
We combined a Delphi consensus procedure of
three iterations (adapted from Hsu and Sanford,
2007) in which experts rated their agreement with
predefined statements in a series of structured
questionnaires with two phases of focus groups
where respondents discussed the items/statements.
The research team (AJ, SZ, CB, RK, MM)
provided the topic lists of the focus groups and
proposed changes of the questions/statements at
each consecutive Delphi round. Scientific experts,
clinical experts, and consumer experts participated
in the Delphi iterations/the focus groups and
responded to the topics/statements. A scientific
expert was defined as “someone who has published
several national or international papers on APs
in care homes.” A clinical expert was defined as
“someone who works in the field of long-term care
and/or is familiar with current literature on AP drug
use”. A consumer expert was defined as “a (former)
caregiver with experience with or interest in APs, or
people with a diagnosis of (mild) dementia.” This
modified Delphi procedure consisted of five phases
(Figure 1).
1. An explorative focus group interview with 20
scientific and clinical experts based on open-ended
questions, in order to generate ideas and identify
core issues.
2. Iteration 1/Questionnaire 1: based on the input
of the exploratory focus group, a first structured
questionnaire was sent out by email to 127 scientific
experts worldwide. The response on the statements
that could be agreed upon or not on a 5-point Likert
scale was used to further refine the questionnaire
for iteration 2.
3. Iteration 2/Questionnaire 2: a second questionnaire
was sent to 46 scientific/clinical experts in the UK,
the Netherlands and Norway with 164 statement
covering eight themes, that could be agreed upon
or not on a 9-point Likert scale (see Table 1).
We also developed a separate questionnaire
for the consumer experts. This questionnaire
consisted of 54 statements, derived from the larger
questionnaire for the scientific/clinical experts and
covered four themes: (1) NPS that may justify
the treatment of APs, (2) provisions that should
be in place before prescription is justified, (3)
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Iteration 3 : Questionnaire 3 
 
  
Task: Identify topics to explore in the study/ draft preliminary 
recommendations 
Who: Handpicked scientific and clinical experts in the UK and the 
Netherlands 
Analysis: Qualitative analysis  
Outcome: 1st questionnaire (99 statements + 28 open ended items) 
Task: Identify level of agreement and disagreement  among experts on the importance of recommendations 
Who: Scientific experts world-wide 
Analysis: Median for central tendency and IPRAS for level of disagreement, qualitative analysis of 
additional comments 
Outcome: 2nd questionnaire  (164 statements) 
Task: Identify level of agreement and disagreement  among experts on the importance of recommendations 
Who: Clinical/scientific experts in three countries 
Analysis: Median for central tendency and IPRAS for level of disagreement, qualitative analysis of 
additional comments 
Outcome: Preliminary list of recommendations with consensus. Focus group topic list including summary 
of disputes and other issues 
Task: Clarify disputes, specify recommendations 
Who: Clinical/scientific experts from three countries 
Analysis: Qualitative analysis 
Outcome: 3rd questionnaire (71 statements) 
 
Task: To collect opinions and concerns of consumer 
experts 
Who: Former and current caregivers and caretaker 
Analysis: Qualitative analysis 
Outcome: Input for 3rd questionnaire 
Task: Identify level of agreement and disagreement  among experts on the 
importance of recommendation  
Who: Clinical/scientific experts in three countries 
Analysis: Median for central tendency and IPRAS for level of 
disagreement, qualitative analysis of additional comments 
Outcome: Final list of recommendations with consensus 
Figure 1. Delphi process.
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Table 1. Response rate and professional division of respondents
ITERATION FOCUS GROUP ITERATION 1 ITERATION 2 FOCUS GROUP ITERATION 3
Total number N = 15 N = 40 N = 34 N = 21 N = 33
............................................................................................................................................................................................................................................................................................................................
Geographical coverage NL, UK International NL, N, UK NL, N, UK NL, N, UK
Key professional expertise
(Old Age) Psychiatrist 10 29 14 13 15
Neurologist – 2 – – –
Geriatrician – 3 8 2 8
Elderly care physician 2 – – 3 –
Nurse – 1 1 1 1
Nurs home doctor/GP – 2 2 1 2
Scientist – 3 – – –
Policy maker 2 – – – –
Clin Pharmacologist – – 5 – 4
Spec fam. medicine 1 – 2 – 2
Clinical Psychologist – – 1 1 1
Pharmacist – – 1 – –
aThe focus group of consumer experts was organized in the UK and consists of six former caregivers, two current caregivers and one person
with dementia.
the threshold at which prescription is justified,
(4) consultation with family caregiver about AP
treatment. Statements that were agreed upon were
entered in the practice guideline. Statements that
were not agreed upon were discussed in the clinical
experts and consumer experts focus groups.
4. Intermediate focus groups: four focus groups were
organized: three with clinical experts (one at each
country) and one with consumer experts from the
UK. The consumer experts were recruited via
Alzheimer’s Society’s Network in the UK. The
themes of the focus groups were based on the
controversies of the second questionnaire. The
input from the focus groups was used to specify
the statements further and to formulate some new
ones.
5. Iteration 3/questionnaire 3: the third questionnaire
was developed in the same format as the previous
and was sent out to the same experts, who
participated in iteration 2. In the final phase of
the study, we collected all statements on which
there was agreement. These were summarized into
a recommendation guideline.
Analysis
Weused two criteria, specified in the RAND/UCLA
appropriateness method, for measuring the level
of agreement and determine consensus; namely
the median rating and the inter-percentile range
(IPR) adjusted for symmetry (IPRAS). The median
was calculated to measure central tendency. IPRAS
was calculated to measure the level of dispersion
of the ratings. IPRAS is the threshold beyond
which the IPR for a particular item indicates
disagreement. Statements with a median between
7 and 9, and on which there was agreement, when
the IPRAS was controlled for, were included in the
guideline, unless additional comments motivated
further specification or clarification.
The focus group discussions were recorded and
transcribed verbatim to capture the exact words
and phrases of the participants. The transcriptions
were then analysed qualitatively by analyzing
the content of the topics and grouping similar
arguments together.
Results
Participants involved
A total of 40 respondents participated in the first
iteration (31% of those invited). In the second
iteration, a total of 34 experts participated (74% of
those invited). In the third iteration, 31 experts par-
ticipated (89% of those invited). Professionals were
(old age) psychiatrists, neurologists, geriatricians,
elderly care physicians (Koopmans et al., 2010), a
GP, nurses, clinical pharmacologist, and a clinical
psychologist. Of the 34 respondents in the second
iteration, 21 participated in the focus group (5 in
the Netherlands, 10 in Norway, and 6 in the UK).
Fourteen consumer experts with experience with
APs (7% of the 196 invited) agreed to participate
in the second iteration, of which 9 participated in
the intermediate focus group and the third iteration.
Six of these were former caregivers, 2 were current
caregivers with a parent who had been prescribed
APs. One participant was diagnosed with dementia,
but was not prescribed AP medication (Table 1).
Agreement on statements
Respondents reached agreement with median
values between 7 and 9 on 119 of 164 statements
in the second and 31 out of 71 statements in the
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Figure 2. Origin and reﬁnements process of the statements during Delphi round iteration 2, intermediate focus group, and iteration 3.
third questionnaire. The third questionnaire was
obviously shorter because items that were agreed
upon were left out of the next questionnaire. The
consumer experts questionnaire consisted of 54
statements of which 15 were specifically added
by this group. The consumer experts reached
consensus on 45 out of 54 statements, including
9 out of the 15 statements that were brought up
by this group. In total, the respondents reached
agreement on 150 statements with median score
between 7 and 9 that were included into the
guideline. (Table 2). During theDelphi process and
focus group some statements that were not agreed
upon were further refined, of which some of them
reached final agreement. Examples were as follows:
electrocardiogram was advised before prescription
only in patients with increased cardiovascular risk,
APs should not always be prescribed in cases of
acute aggression but only when patient’s behavior
cause acute danger to themselves, other patients or
other people. The origin and the refine process of
the statements are depicted in Figure 2.
Table 2. Results iteration 2 and 3
ITERATION ITERATION 2 ITERATION 3
Number of statements n = 164 n = 71
........................................................................................................................................................
Median 7–9/consensusa 119 31
Median 4–6/consensus 24 14
Median 1–3/consensus 8 11
Median 7–9/disagreement 2 2
Median 4–6/disagreement 11 11
Median 1–3/disagreement 0 2
Note: The statements of iteration 1 were rated dichotomous or on
a 1–5 Likert scale and could not be analysed using the
RAND/UCLA criteria. Therefore, this iteration has been excluded
from this table. aOnly statements with median 7–9/consensus were
copied into the guideline.
Content of the statements/practice guideline
The full version of the practice guideline is attached
as supplementary file (supplement 1). The guideline
addresses five main themes of which the main
issues are described below (Table 3). Some more
and detailed information about the themes were
http://dx.doi.org/10.1017/S1041610215000745
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Table 3. Themes and highlights of statements addressed in the practice guideline for antipsychotic prescription
in dementia patients residing in long-term care
1. General prescription stipulations.
• Antipsychotics should never be used as a first-line approach. Non-pharmacological interventions should be tried
first. The benefits should be expected to outweigh the adverse events.
• APs should only be prescribed in
(a) symptoms caused by underlying psychotic disorder that causes severe distress to patient/risk to others,
(b) in non-psychotic patients in an extreme and acute situation with risk i.e. severe and harmful physical aggression
to oneself or other, severe physical exhaustion, and severe eating/drinking disorders with a risk of
malnourishment or dehydration.
• The behavior is not caused by another somatic disorder (such as pain, infection, hunger, constipation) or
psychiatric disorder (anxiety/depression),
• only antipsychotics with proven evidence should be prescribed,
• start low, go slow.
2. Assessment prior to prescription.
• Investigation of underlying syndromes, neurological, psychiatric, environmental (interaction) factors.
• Assessment of medical state and risk (cardiovascular and subtype of dementia (Lewy Body/Parkinson) and
symptoms (motor symptoms, cardiac arrhythmias, orthostatic hypotension, urine retention).
• ECG should be carried out in patients with history of cardiovascular diseases, cardiac arrhythmia, and combination
of medication that prolong QT-interval.
3. Care and treatment plan.
• Use APs always in combination with non-pharmacological and preventive measure aimed at increasing carers
competence.
• Care and treatment plan should draw expertise form multidisciplinary team/with regular consultation.
• Family caregiver should be informed and consulted throughout treatment and discontinuation.
• Improvement and lack of improvement should be included as a clinical criterion for modifying care and treatment
plan.
4. Discontinuation.
• Discontinuation should be a standard principle as part of a withdrawal plan.
• If APs are prescribed for sedative purposes, drug should be withdrawn when situation has calmed down.
• Discontinuation through tapering rather than immediate discontinuation unless Malign Neuroleptic Syndrome,
cardiovascular complication, infections, severe side effect at low dose.
5. Long-term treatment (> 12 weeks).
• Long-term antipsychotic treatment is only acceptable in patients with
◦ long history or high severity of psychotics/concurrent schizophrenia,
◦ at least two unsuccessful discontinuation attempts + psychosocial interventions has been shown not to be
effective + alternative medication is not available/has been shown ineffective/expected to cause severe
adverse events.
• Restarting can be acceptable – under supervision of a specialist – in extreme situation in case of
◦ recurrence of severe symptoms after withdrawal resulting in risk/distress that had previously improved with AP
treatment,
◦ recurrence of severe symptoms after withdrawal if withdrawal was before completing a 12-week course,
◦ a distinct separate new episode.
collected in three attachments about (1) threshold at
which APs can be prescribed, (2) assessment prior
to prescription, and (3) care and treatment plan.
The statements of the attachments were also a result
of the Delphi process.
GENERAL PRESCRIPTION STIPULATIONS
In the guideline, a distinction was made between
prescribing an AP for treatment of severe symptoms
(physical or severe verbal aggression or agitation or
severely distressing anxiety) that are caused by an
underlying psychotic disorder and prescription for
sedative purposes in extreme and acute situations
without psychosis. In the former case, APs should
be given as long as this is needed for the treatment
of psychosis, in the latter prescription should be
withdrawn when the situation has calmed down.
APs for an underlying psychotic disorder can
only be prescribed in case of severe continuous
distress affecting quality of life of the patient,
family caregiver, or other patients; the behavior
is not caused by another somatic disorder (such
as pain, infection, hunger, constipation) or psy-
chiatric disorder (anxiety/depression); moreover,
psychosocial interventions have been tried without
success and if the benefit is expected to outweigh
the adverse events. AP drug prescription might
be justified in case of an extreme situation (also
http://dx.doi.org/10.1017/S1041610215000745
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without psychosis), if the behavior is causing acute
and tangible risks to patient or other. Symptoms
that may indicate an extreme situation are severe
and harmful physical aggression, severe physical
exhaustion, and severe eating/drinking disorders
with a risk of malnourishment (weight loss) or
dehydration.
ASSESSMENT PRIOR TO PRESCRIPTION
Before prescription of APs, proper assessment
should be carried out of the target symptom(s) that
warrant treatment, underlying medical causative
factors (pain, infection, hunger, constipation), other
psychiatric co-morbidities (depression, anxiety,
sleep disorders, and delirium), social factors; and
risk groups that may affect the decision to prescribe
APs or not in the first place (cardiovascular diseases,
cardiac arrhythmia, Lewy Body Dementia (LBD),
and Parkinson’s disease). Baseline assessment of
motor symptoms, cardiac symptoms, orthostatic
hypotension, and urinary retention that could be
mixed up with side effects, should be carried out.
Electrocardiogram was only deemed necessary in
patients with a history of cardiovascular disease
(including cardiac arrhythmias) or in patients with
other medication that can prolong QT-interval.
CARE AND TREATMENT PLAN/FAMILY
INVOLVEMENT
AP treatment should always be combined with
non-pharmacological interventions and preventive
measures aimed at increasing caregivers compet-
ence to deal with NPS. The AP prescription should
be part of the care and treatment plan which
should include a further definition and specification
of target symptom, associated risks and distress,
treatment objective, how and when improvements
and adverse events should be monitored. The
patient (if relevant) and primary family caregiver
should be consulted in the critical phases of
treatment: before treatment, during monitoring,
discontinuation and in case of long-term treatment.
The most responsible clinician, rather than the
nurse’s, should actively discuss the care and
treatment plan with the family caregiver. This is
usually the general practitioner, but depending
on the way care is organized on a local or
national level, this could be the elderly care
physician or the consulting old-age psychiatrist.
The treatment plan should also include routines
for multidisciplinary consultation from the most
responsible doctor, other consulting clinicians,
nurse, relevant (in)formal caregiver. This team is
responsible for monitoring AP treatment. An old-
age psychiatrist should be consulted in severe cases
that cannot be solved by the responsible physician.
DISCONTINUATION
In case of prescription for psychosis and for
sedative purposes, APs should be discontinued
when the NPS (partly) resolve or the acute
situation has calmed down. Discontinuation should
be performed through tapering, to be able to
monitor any relapse of symptoms, unless in cases
of malign neuroleptic syndrome, cardiovascular
events, infection or severe side effects (when the
dose is low). In case of lack of improvement, the
dose should be increased until side effects appear,
and continued for a period of 4 weeks. If no
improvement is observed after this period, APs
should be withdrawn through tapering. Also, the
diagnosis, target symptoms and treatment goals
should be reviewed and alternative interventions or
other agents should be considered.
LONG-TERM TREATMENT (>12 WEEKS)
Treatment of APs should not exceed 12 weeks.
Longer treatment is only acceptable in cases of
psychosis or schizophrenia or justified for the treat-
ment of severe symptoms associated with dementia
if two discontinuation attempts did not turn out
to be successful, and psychosocial interventions or
alternative psychotropicmedication has been shown
ineffective. Long-term treatment should always be
handled by a specialist.
Discussion
With the robust process of modified Delphi
technique along with focus groups, that involved
a large number of scientific, clinical, and consumer
experts, we ended up with a set of 150 statements
that were incorporated into a practice guideline, and
that is ready to be used by professionals working
with people with dementia in long-term care. The
practice guideline provides clinicians key practical
information that is lacking in current guidelines.
Discussion of the guideline content
We were able to answer some key topics that are not
sufficiently addressed in other practice guidelines.
A MORE REFINED DEFINITION OF
PRESCRIPTION INDICATION AND
THRESHOLD TO PRESCRIBE APS IN
AGITATION, AGGRESSION AND PSYCHOSIS
In this guideline, a differentiation was made for
AP as treatment for psychosis and as sedation to
cope with aggression but only in extreme or acute
specified situations for a relatively shorter period.
This differentiation is novel, since current clinical
trials and practice guidelines do not distinguish
http://dx.doi.org/10.1017/S1041610215000745
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between the two indications. The AAGS/AGP
guideline (AAGS/AGP, 2003) only allows APs
in behavior associated with psychosis; the Nice
guideline (NICE guideline 42) allows medication in
psychosis and/or agitation; the Canadian guideline
(Canadian Guideline for senior mental health,
2006) sets the indication to behavior with or without
psychosis but in the latter case not only restricted
to acute circumstances. Only the expert panel of
the DICE approach seems to somewhat distinguish
two indications by stating that psychotropics may
be prescribed for psychosis causing (potential to)
harm and aggression causing risk to self or others
(Kales et al., 2014). Although, there is some
evidence for APs in the reduction of aggressive
symptoms without psychosis (Ballard et al., 2009b),
experts evidently believe that the prescription of
APs in aggression without underlying psychosis
is more sedation rather than symptom resolution
through treatment. That is also the reason why
the threshold for prescription in non-psychotic
acute aggression is advised to be higher than
in aggression associated with psychosis. This
differentiation among symptoms like aggression,
agitation, and psychosis is in line with the more
syndromal approach of diagnosing NPS (Lyketsos,
2007). The differentiation between psychosis and
acute phase of aggression would also imply that
the treatment duration for acute reasons (in non-
psychotic extreme aggression) may be shorter
than for the treatment of psychosis. When the
situation has calmed down, there is no place
for APs and there will be time to consider
other (non-) pharmacological management of
aggression/agitation.
A BROADER DESCRIPTION OF RISK
FACTORS THAT SHOULD BE CONSIDERED
BEFORE PRESCRIPTION
Before starting AP treatment, a thorough assess-
ment of underlying syndromes, medical state, and
risk factors should be carried out, which is in line
with the AGS/AAGP paper (AGS/AAGP, 2003)
and the US DICE approach (Kales et al., 2014).
Increasingly important is the careful monitoring
of pain as a possible (Pieper et al., 2013),
under-recognized (De Souto Barreto et al., 2013)
and treatable (Husebo et al., 2014) underlying
medical factor, which is also acknowledged in
the Nice guideline (NICE guideline 42), and
the US DICE approach (Kales et al., 2014).
The novelty of the present guideline is the focus
on prior assessment of symptoms that may be
recognized as adverse effects (urine retention),
and the clear focus on prior assessment of
cardiovascular risk factors. In the focus groups,
there was some discussion on the necessity of
making an electrocardiogram to measure the QT-
interval. Since the pre-test risk of prolonged QT
interval in the general population is low, experts
consider carrying out electrocardiogram in all
patients before AP treatment not feasible and
not efficient, but only in a subgroup of patients
with higher pre-treatment risk with a history
of cardiovascular diseases, cardiac arrhythmia,
and a combination of medications that prolong
QT-interval, which may include among others
citalopram, escitalopram,methadone, ondansetron,
and azithromycine (Trinkley et al., 2013). Not only
LBD, but Parkinson dementia (PDD) was also
recognized as a risk factor for severe motor adverse
events from APs. So recognition of LBD/PDD is
vital before AP drug prescription.
CIRCUMSTANCES AT WHICH APS SHOULD
BE STOPPED OR TAPERED
Practical advice on discontinuation is very
necessary, given the reports of prolonged AP drug
use in nursing homes (Wetzels et al., 2011).
Although there are numerous stop trials, there is
no indication whether immediate discontinuation
(Ballard et al., 2009a) or tapering (Devanand et al.,
2012) should be preferable over the other. In this
guideline, experts favor tapering of APs, also to
monitor any symptom relapse at lower dosage.
PROVIDING SPECIFIC CRITERIA FOR
JUSTIFYING LONG-TERM TREATMENT
Although the general advice is to discontinue
APs after 12 weeks in agitation or psychosis
associated with dementia, there may be room
for prolonged treatment in some specific circum-
stances. Although, in general, prolonged AP use
may not be effective (Schneider, 2006), there is
some conflicting evidence of its long-term efficacy.
Although, stopping APs has proven to be feasible
(Ruths et al., 2008; Ballard et al., 2009a; Declerq
et al., 2013), there may be subgroups of patients
with high level of NPS (Ballard et al., 2009a)
or patients with previous response to risperidone
(Devanand et al., 2012) in which stopping after
long-term treatment is associated with a relapse of
symptoms. The present guideline is stricter in the
maximum prescription duration (12 weeks instead
of 6 months in the AGS/AAGPS guideline), but at
the same time allow practitioners to prescribe APs
for a longer period of time under strict predefined
circumstances, although long-term prescription
requires active involvement/supervision of a
specialist (e.g. old age psychiatrist).
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A BROADER INVOLVEMENT OF
MULTIDISCIPLINARY EXPERTISE AND THE
ROLE OF THE FAMILY CAREGIVER IN THE
PROCESS OF AP PRESCRIPTION
Long-term care for people with dementia is
multidisciplinary care. It is in this context
that AP drug prescription should be initiated,
monitored, and tapered. Since AP prescription
should be considered in concert with psychosocial
interventions, important decisions should be made
in a multidisciplinary context and if necessary with
external expertise.
In the focus group of consumer experts, the
role of the family caregiver was considered very
important not only in the decision to prescribe
APs but also in case of dose change and stopping.
Also the monitoring plan should be discussed with
the family. Since prescription of APs is a medical
decision, the physician rather than the nurse should
discuss the care plan with the family. Current
practice shows that only 62% of the caregivers
consented the prescription of AP treatment and
84%of those find their opinion sufficiently weighted
by the physician in the decision to prescribe AP
(Cornegé-Blokland et al., 2012). There is clearly
room for improvement. The focus group did not
discuss the nature of decision making (informed,
consent, shared decision making).
Implications for clinical practice/advices for
implementation
This practice guideline reveals novel components
that are expected to move practice beyond current
guidelines. Scientific guidelines, although robustly
weighing efficacy and risks of psychotropic drugs in
clinical trials or meta-analyses, fail to address under
which circumstances drugs should be prescribed,
tapered, and under which circumstances long-
term treatment is justified, since no studies on
this specific conditions are conducted. Clinicians
lack the step from “what to prescribe” towards
“how to prescribe” which is not addressed by
scientific guidelines. Thus, specifying indications
for APs drug prescription and conditions for taper-
ing/stopping and long-term treatment could help
to lower unnecessary high prescription rates. Also,
the recommendations about what risks factors and
adverse effects should be assessed and monitored is
expected contribute to a safer AP drug use. Another
key issue is the consultation of family caregiver in all
stages of prescription. The active involvement of the
family caregiver as a legal representative – especially
in a shared-decision making model – could
contribute to a more careful consideration of AP
drug prescription and prevent long-term drug use.
This guideline provides useful tools to bridge the
gap between scientific guidelines and clinical prac-
tice. Distribution of the guideline through national
Alzheimer’s organization and bodies representing
general physician’s, old age psychiatrists, geriatri-
cians, and elderly care physician’s would facilitate
implementation of the guideline. The implementa-
tion of this guideline by clinicians is expected to im-
prove the quality of psychotropic drug prescription.
Strengths and limitations
We want to emphasize that the practice guideline,
that has been produced by cooperation between
experts in UK, Norway, and the Netherlands, can
be used in Western European and perhaps other
developed countries, but may not be generalized
to other countries in the world. A strength of this
guideline is the extensive underlying procedure in
which not only scientific and clinical experts but also
consumer experts were able to reach agreement.
Furthermore, the novel approach of a combination
of the modified Delphi process and focus group has
added value for three reasons. First, rather than just
forcing the experts to agree or disagree with pre-
defined statements, they were actively involved in
specifying the statements so that more consensus
could be achieved. We considered this an important
modification, for the same reasons that have been
put forward by critics of traditional Delphi, namely
that the method does not allow respondents to
discuss issues raised or to elaborate on their views
(Goodman, 1987; Walker and Selfe, 1996). An
interaction between experts can enhance complex
decision-making processes and clarify language
and recommendations (Vakil, 2011). Instead of
excluding the initial statement that cannot be
agreed upon from the guideline, as would be the
normal procedure in the Delphi method, we re-
formulated the recommendation to ensure that it
was both specific enough to be clinically relevant,
and supported by the consensus view of a large
pool of experts. Second, we adopted a method
for calculating consensus that accounted for the
dispersion of ratings among the respondents as well
as the internal symmetry between ratings. Third,
we combined different sources of experience –
scientific, clinical, and consumer-based experience,
and included experts from various professions. By
including consumer experts, we also integrated the
patient and caregiver perspective into the study,
as opposed to restricting patient involvement to
only reflecting on the final outcome. This gave the
statements a strong support-base, which increases
the legitimacy of the final recommendations. A
limitation is the relative low number of consumer
experts responding to the second questionnaire
http://dx.doi.org/10.1017/S1041610215000745
Downloaded from http:/www.cambridge.org/core. Kings College London, on 13 Oct 2016 at 15:54:20, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
1858 S. U. Zuidema et al.
(n = 14) and participating in the focus group (n =
9), which may result in sampling error. Moreover,
the focus group is only organized in the UK, due to
practical reasons, which may limit generalizability
of the caregiver perspective to other countries.
Conclusion
With this practice guideline, we were able to bridge
the gap between scientific evidence (as formulated
in the scientific guidelines) and daily practice.
Although the guideline is not a substitute for
evidence-based guidelines, it provides an additional
level of detail to inform clinical practice for further
clinical decision making. The method has led to a
formal consensus that uniquely combined patients
as well as clinicians’ views. Most important, the
modified Delphi process turned out to have added
value because it contributed to resolution of several
gaps that were unanswered or not addressed in
previous practice guidelines. This method could
also be used by producing other practice baseline
guidelines for other patient groups.
We recommend that this guideline is translated
into national languages in Western Europe,
disseminated and implemented into clinical
practice. This may help physicians working with
people with dementia in long-term care to reduce
inappropriate AP drug prescription.
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